Boehringer Ingelheim is delighted to announce the 2019-2020 veterinary student scholarship programme. This programme reflects Boehringer Ingelheim’s long-term commitment to promoting health and well-being of farm animals.
Through the BVDzero Scholarship Programme, Boehringer Ingelheim aims to create awareness of BVD in veterinary students. In addition, the company believes that such initiatives will help increase BVD awareness in general and, as a result, help reduce its prevalence.
BVDzero Scholarship Programme criteria
The BVDzero Committee, in collaboration with a representative of the World Association for Buiatrics, will identify outstanding veterinary students from around the world who can help address the ever-changing industry and the health, food, and welfare needs of the veterinary community.
There will be 10 student scholarships of 1,000 euro awarded to each student.
Each scholarship winner will also receive free registration and accommodation at the upcoming World Buiatrics Congress in Madrid in 2020, compliments of Boehringer Ingelheim.
Students selection criteria
- Second, third and fourth-year veterinary student
- Passion for livestock, particularly for cattle industry
- Demonstration of academic excellence
- Demonstration of leadership and participation in non-university activities
Application requirements and deadline
The application period closes on May, 25 2019.
The application form can be downloaded by clicking on the following link: http://www.bvdzero.com/bvd_news/bvdzero-scholarship-programme.
The Boehringer Ingelheim Animal Health Business Unit and its BVDzero team encourage qualified students to submit their applications and wish success to all the candidates.
The company plans to continue this initiative in the future.
Visit www.bvdzero.com for more updates.
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 percent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success rather than short-term profit. The company therefore aims at organic growth from its own resources, with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility toward mankind and the environment.
About Boehringer Ingelheim Animal Health
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales in 2017 of 3.9 billion euros ($4.4 billion) and around 10,000 employees worldwide, we are present in more than 150 markets. For more information, visit here: https://www.boehringer-ingelheim.com/animal-health/overview.